The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the ... One by one, its generation of biotech firms, like Abgenix, Cambridge Antibody Technology and Celltech, has been ...
Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval of Cobenfy (KarXT), a new treatment for schizophrenia. Recent research published in The American Journal of Psychiatry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback